Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 13/20 | 0.43 |
| ▸ | FPR1 | P21462 | 12/20 | 0.43 |
| ▸ | F10 | P00742 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6366128 | 0.84 | FPR2 (0.45) | ALDH1A1FPR2FPR1F10 | |
| SCHEMBL14488829 | 0.84 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2FPR2FPR1F10 | |
| SCHEMBL6361301 | 0.83 | FPR2 (0.44) | FPR2FPR1F10 | |
| SCHEMBL6361948 | 0.83 | FPR2 (0.48) | FPR2FPR1F10 | |
| SCHEMBL5720791 | 0.81 | F10 (0.56) | ALDH1A1FPR2FPR1F10 | |
| SCHEMBL6366526 | 0.81 | F10 (0.56) | ALDH1A1FPR2FPR1F10 | |
| SCHEMBL6367603 | 0.80 | FPR2 (0.60) | ALDH1A1SMN1; SMN2FPR2FPR1F10 | |
| SCHEMBL6361329 | 0.79 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2FPR2FPR1F10 | |
| SCHEMBL6362460 | 0.79 | F10 (0.58) | FPR2FPR1F10 | |
| SCHEMBL6363124 | 0.79 | F10 (0.57) | FPR2FPR1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235544-B2 | for use in conjunction with thrombolytic agents, thus permitting the use of a lower dose of thrombolytic agent; treatment of acute vascular diseases; may have potential in neurogenerative diseases such as Parkinson's and Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-06-26 | — | — | US | disclosed |
| US-20060178419-A1 | 3-Sulfonylamino-pyrrolindine -2- one derivatives as inhibitors of factor xa | GLAXO GROUP LIMITED (GB) | 2006-08-10 | — | — | US | disclosed |
| EP-1641752-A1 | 3- SULFONYLAMINO- PYRROLIDINE- 2- ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2006-04-05 | — | — | EP | disclosed |
| WO-2004110997-A1 | 3- SULFONYLAMINO- PYRROLIDINE- 2- ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178419-A1 | 3-Sulfonylamino-pyrrolindine -2- one derivatives as inhibitors of factor xa | TFPI, SERPINC1, TFPI2 | ALDH1A1 1138/4885SMN1; SMN2 3081/4885FPR2 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.